Retatrutide side effects reported in clinical trials have most often involved the digestive system, including nausea, diarrhea, vomiting and constipation. Researchers have also observed dose-related increases in heart rate and less common events that require continued study. Retatrutide remains investigational and is not approved by the U.S. Food and Drug Administration (FDA).
Last reviewed: October 25, 2026. This article is for education only and is not medical advice. It does not provide dosing, administration or treatment instructions.
What Side Effects Have Retatrutide Trials Reported?
Retatrutide is a once-weekly investigational medicine designed to activate GIP, GLP-1 and glucagon receptors. Because it is still being evaluated, its complete safety profile has not been established. The most detailed peer-reviewed safety information comes from controlled clinical trials rather than products sold online.
In the 48-week Phase 2 obesity trial, 73% to 94% of participants in the retatrutide groups reported at least one adverse event, compared with 70% in the placebo group. The percentage varied by study dose and was highest in the 8 mg and 12 mg groups. An adverse event does not automatically mean the study medicine caused the event, but researchers track all such events to identify patterns.
Most commonly reported gastrointestinal effects
- Nausea
- Diarrhea
- Vomiting
- Constipation
These gastrointestinal events were generally mild to moderate. They occurred mainly while doses were being increased, were more common at higher study doses and were the most frequent reason participants stopped treatment because of an adverse event. A lower starting dose reduced some gastrointestinal effects within the trial, but this observation should not be treated as personal dosing guidance.
Heart-rate changes
Investigators reported a dose-dependent increase in heart rate that peaked at approximately 24 weeks and then declined. Mild-to-moderate rhythm-related events were reported, along with one severe prolonged-QT event in a participant who was also taking ondansetron. These findings require clinical interpretation and continued monitoring in larger studies.
Other events observed in the Phase 2 trial
Other findings included temporary increases in liver enzymes in a small percentage of participants, asymptomatic increases in amylase and lipase, one serious event of acute pancreatitis, and gallbladder-related events. Skin sensitivity or cutaneous hyperesthesia was reported in 7% of retatrutide participants and 1% of placebo participants; these events were not severe or serious in that trial.
| Finding | What the evidence says | Important limitation |
|---|---|---|
| Digestive symptoms | Most frequently reported; generally mild to moderate and more common during dose escalation. | Trial findings cannot predict an individual response. |
| Increased heart rate | Dose-related increases were observed and later declined in the Phase 2 trial. | Longer-term cardiovascular safety still requires evaluation. |
| Serious adverse events | Occurred in 4% of retatrutide participants and 4% of placebo participants in Phase 2. | A trial of 338 adults cannot detect every rare risk. |
| Treatment discontinuation | Occurred in 6% to 16% of retatrutide participants because of adverse events. | Rates varied by study group and dose. |
What Did Phase 3 Research Add?
The Phase 3 TRIUMPH-1 study enrolled 2,335 adults with obesity or overweight and followed participants for 80 weeks. The peer-reviewed report published in September 2026 again identified gastrointestinal events as the most common adverse events. The study provides a larger and longer evidence base than Phase 2, but it does not remove the need for regulatory review or longer-term surveillance.
ClinicalTrials.gov lists TRIUMPH-1 as completed. Other retatrutide studies continue to examine different populations and outcomes. Results from one trial should not be generalized to every person, particularly people who would not have met the study eligibility criteria.
Is Retatrutide FDA Approved?
No. As of October 25, 2026, retatrutide is not FDA approved and is not legally available to consumers as an approved prescription medicine. The FDA states that retatrutide cannot be used in compounding under federal law and has not been found safe and effective for any condition. Eli Lilly likewise states that legitimate retatrutide is available only through its authorized clinical trials.
Products advertised online as “research-grade,” compounded or generic retatrutide are not the same as the medicine evaluated in controlled Lilly trials. Their identity, purity, strength and storage cannot be assumed. The trial safety data in this article should not be applied to an unverified product.
For a broader explanation of the compound and its development status, read Retatrutide: What It Is, Trial Status and Research Explained.
What Do the Trial Results Not Tell Us Yet?
- The complete long-term safety profile after years of use
- The frequency of very rare adverse events in a much larger population
- How safety may differ across medical conditions and medication combinations
- How real-world outcomes may compare with tightly controlled trials
- Whether benefits and risks will lead regulators to approve specific indications
This uncertainty is normal for an investigational medicine. Regulatory agencies review the complete evidence package—including manufacturing quality, benefits, risks and labeling—rather than a single headline result.
Frequently Asked Questions About Retatrutide Side Effects
What are the most common retatrutide side effects?
The most commonly reported effects in clinical trials have been gastrointestinal, especially nausea, diarrhea, vomiting and constipation. They were generally mild to moderate and occurred most often during dose escalation.
Can retatrutide increase heart rate?
A dose-related increase in heart rate was observed in the Phase 2 trial. It peaked at about 24 weeks and then declined. Researchers continue to evaluate cardiovascular safety in the broader clinical program.
Did serious adverse events occur?
Yes. Serious adverse events occurred in both the retatrutide and placebo groups in Phase 2, at 4% in each. The trial also recorded one serious acute-pancreatitis event. Larger and longer studies are needed to characterize uncommon risks.
Is retatrutide safe to buy online?
No online product should be assumed to be authentic retatrutide. The FDA says retatrutide is unapproved and cannot lawfully be used in compounding. Products sold outside authorized clinical trials may have unverified identity, purity or strength.
How is an adverse event different from a proven side effect?
An adverse event is any unfavorable medical occurrence during a study, whether or not investigators determine that the treatment caused it. Researchers compare patterns between treatment and control groups and examine timing, dose relationships and biological plausibility.
